Marinus Pharmaceuticals Inc (MRNS) Expected to Announce Earnings of -$0.30 Per Share
Brokerages predict that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will report ($0.30) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Marinus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.30). Marinus Pharmaceuticals reported earnings per share of ($0.20) in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The firm is scheduled to announce its next earnings report on Tuesday, March 5th.
On average, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.87). For the next year, analysts forecast that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.19) to ($0.45). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Marinus Pharmaceuticals.
Several research firms have commented on MRNS. Cantor Fitzgerald set a $22.00 price target on Marinus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 26th. ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 16th. Mizuho restated a “buy” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, December 11th. LADENBURG THALM/SH SH set a $22.00 price target on Marinus Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 11th. Finally, Svb Leerink restated an “outperform” rating on shares of Marinus Pharmaceuticals in a report on Wednesday, February 6th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Marinus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $18.44.
In other news, CEO Christopher Michael Cashman sold 8,142 shares of the business’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $3.13, for a total transaction of $25,484.46. Following the completion of the sale, the chief executive officer now owns 239,761 shares in the company, valued at approximately $750,451.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.60% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in Marinus Pharmaceuticals by 190.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock worth $754,000 after acquiring an additional 69,863 shares during the period. Partner Fund Management L.P. purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $17,741,000. Tekla Capital Management LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $3,362,000. Credit Suisse AG boosted its holdings in Marinus Pharmaceuticals by 673.8% in the 3rd quarter. Credit Suisse AG now owns 1,033,326 shares of the biopharmaceutical company’s stock worth $10,334,000 after acquiring an additional 899,780 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in Marinus Pharmaceuticals by 21.9% in the 3rd quarter. Alps Advisors Inc. now owns 71,706 shares of the biopharmaceutical company’s stock worth $717,000 after acquiring an additional 12,905 shares during the period. Institutional investors and hedge funds own 68.55% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Recommended Story: How Investors Can Profit from Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.